UK-based Mission Therapeutics Ltd has raised $15 million from a group of institutions led by Pfizer Ventures, the venture capital arm of Pfizer Inc. The capital will enable to company to advance its portfolio of preclinical small molecule drugs that inhibit deubiquitylating enzymes (DUB) which are involved in DNA damage response. The company’s therapeutic focus is neurodegenerative disorders, mitochondrial diseases and fibrosis.
